Get the Stockscreener App
6.895
6.67%
0.445
Savara Inc stock is traded at $6.895, with a volume of 4.63M.
It is up +6.67% in the last 24 hours and up +72.00% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$6.45
Open:
$6.46
24h Volume:
4.63M
Relative Volume:
2.48
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-20.89
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+9.21%
1M Performance:
+72.00%
6M Performance:
+195.28%
1Y Performance:
+104.76%
1-Day Range:
$6.42
$6.91
1-Week Range:
$6.18
$6.88
52-Week Range:
$1.89
$6.88
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.895 | 1.31B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.98 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.47 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
894.57 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.75 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
194.50 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara stock hits 52-week high at 6.61 USD By Investing.com - Investing.com Canada
Certain Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
172,836,922 Common Stock of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Affinity Asset Advisors LLC Purchases New Stake in Savara Inc. $SVRA - MarketBeat
Savara issues patent for Molbreevi from European Patent Office - MSN
Savara rumor highlighted in Betaville blog - MSN
How strong dollar benefits Savara Inc. (YB4P) stock2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
Dir Elam Acquires 4,387 Of Savara Inc [SVRA] - TradingView
Savara Inc. (SVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Savara Inc. (YB4P) stock supported by free cash flowDip Buying & Daily Price Action Insights - Newser
Savara (NASDAQ:SVRA) Shares Up 6.8%What's Next? - MarketBeat
Savara (SVRA) Stock Analysis Report | Financials & Insights - Benzinga
Savara (NASDAQ:SVRA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Is Savara Inc. stock trading near support levelsRecession Risk & AI Optimized Trade Strategies - Newser
Is Savara Inc. (YB4P) stock a top pick for value investorsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Savara (NASDAQ:SVRA) Nasdaq Today Specialized Biotech Direction - Kalkine Media
Savara Inc. ticks higher amid takeover speculation - MSN
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace
Savara receives European patent for PAP treatment device By Investing.com - Investing.com Canada
Why analysts upgrade Savara Inc. stockTrade Volume Summary & Weekly High Return Forecasts - Newser
Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - MSN
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences - MSN
Savara Inc. (SVRA) Rises Amid Takeover Speculation - GuruFocus
Savara (SVRA) Market Activity Stirred by Acquisition Rumor - GuruFocus
Savara Inc. ticks higher amid takeover speculation (SVRA:NASDAQ) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Shares Gap DownHere's Why - MarketBeat
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com
Savara, PARI Granted European Patent Covering Drug-Device Combination - marketscreener.com
Savara (SVRA) Secures European Patent for Drug-Device Combo - GuruFocus
Savara receives European patent for PAP treatment device - Investing.com
Is Savara Inc. (YB4P) stock a top hedge fund pickBull Run & Verified Stock Trade Ideas - Newser
F m Investments LLC Acquires 91,830 Shares of Savara Inc. $SVRA - MarketBeat
10 Small Caps With Big Double-Digit Gains - Insider Monkey
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 - MSN
Savara Stock Surges Amid Positive Financial Developments and Raised Price Target - timothysykes.com
Savara Inc. Sees Price Target Raised Amid Promising Drug Developments - StocksToTrade
Savara Inc’s Stock Boosted by Strategic Financial Moves and Developments - StocksToTrade
Savara’s Strategic Moves Strengthen Market Position with Price Target Increase - timothysykes.com
Savara Stock: Will It Continue to Rise? - StocksToTrade
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Savara Inc (SVRA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Nov 14 '25 |
Option Exercise |
1.46 |
5,860 |
8,556 |
121,326 |
| Hawkins Richard J | Director |
Jun 20 '25 |
Buy |
2.04 |
48,225 |
98,572 |
115,466 |
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.04%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):